![]() ![]() This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the relevant Canadian securities legislation, including, but not limited to, the statements by Mr. Learn more at or connect with us on LinkedIn.Ĭautionary Note Regarding Forward-Looking Statements Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. in Politics and Greek Classics from New York University.Įndo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Chao was a research fellow at Massachusetts General Hospital/Harvard Medical School as a recipient of the BioMedical Research Career Award and received her B.A. Prior to that, she was a Managing Director and Senior Lead Biotechnology Analyst at RBC Capital Markets and was a Senior Analyst in Biotechnology at Leerink Swann & Co. Chao has experience in investment research, most recently serving as Managing Director and Senior Lead Biotechnology Securities Analyst at Deutsche Bank where she covered large- and small- to mid-cap biotechnology companies. "Jennifer brings a wealth of industry experience and expertise that will be vitally important to Endo as we further advance our strategic priorities," said Blaise Coleman, President and CEO of Endo.Īdditionally, Ms. "Jennifer's deep experience in pharmaceuticals and biotechnology along with her strong financial acumen should be invaluable to Endo as we continue our mission to develop and deliver life enhancing products." "We are pleased to welcome Jennifer to the Endo Board," said Paul Campanelli, Endo's Chairman of the Board. until its acquisition by Endo in December 2020. Chao served as Chairman of the Board of BioSpecifics Technologies Corp. ![]() She is the founder of CoreStrategies Management, LLC, which provides corporate and financial consulting to biotech and life sciences companies. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy. The company was founded in 1997 and is headquartered Dublin, Ireland.Ms. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Branded Pharmaceuticals segment conducts certain operations in the U.S. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |